109 related articles for article (PubMed ID: 24155038)
1. The impact of Girdin expression on recurrence-free survival in patients with luminal-type breast cancer.
Nishimae K; Tsunoda N; Yokoyama Y; Kokuryo T; Iwakoshi A; Takahashi M; Nagino M
Breast Cancer; 2015 Sep; 22(5):445-51. PubMed ID: 24155038
[TBL] [Abstract][Full Text] [Related]
2. [Expression and significance of phosphorylated Girdin in breast cancer].
Xu Y; Fu L; Gu F; Ma YJ
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):205-9. PubMed ID: 22780975
[TBL] [Abstract][Full Text] [Related]
3. Girdin protein expression is associated with poor prognosis in patients with invasive breast cancer.
Choi JS; Kim KH; Oh E; Shin YK; Seo J; Kim SH; Park S; Choi YL
Pathology; 2017 Oct; 49(6):618-626. PubMed ID: 28818465
[TBL] [Abstract][Full Text] [Related]
4. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
5. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
6. Elevated expression of Girdin in the nucleus indicates worse prognosis for patients with estrogen receptor-positive breast cancer.
Peng WT; Hu X; Yao L; Jiang YZ; Shao ZM
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S648-56. PubMed ID: 24793340
[TBL] [Abstract][Full Text] [Related]
7. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
8. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
[TBL] [Abstract][Full Text] [Related]
9. Expression of girdin in human colorectal cancer and its association with tumor progression.
Jun BY; Kim SW; Jung CK; Cho YK; Lee IS; Choi MG; Choi KY; Oh ST
Dis Colon Rectum; 2013 Jan; 56(1):51-7. PubMed ID: 23222280
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
[TBL] [Abstract][Full Text] [Related]
11. Expression of ALDH1 in axillary lymph node metastases is a prognostic factor of poor clinical outcome in breast cancer patients with 1-3 lymph node metastases.
Nogami T; Shien T; Tanaka T; Nishiyama K; Mizoo T; Iwamto T; Ikeda H; Taira N; Doihara H; Miyoshi S
Breast Cancer; 2014 Jan; 21(1):58-65. PubMed ID: 22407396
[TBL] [Abstract][Full Text] [Related]
12. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
Criscitiello C; Disalvatore D; De Laurentiis M; Gelao L; Fumagalli L; Locatelli M; Bagnardi V; Rotmensz N; Esposito A; Minchella I; De Placido S; Santangelo M; Viale G; Goldhirsch A; Curigliano G
Breast; 2014 Feb; 23(1):69-75. PubMed ID: 24314620
[TBL] [Abstract][Full Text] [Related]
13. Expression of tumor necrosis factor receptor-assicated factor 4 correlates with expression of Girdin and promotes nuclear translocation of Girdin in breast cancer.
Wang A; Wang J; Sun L; Jin J; Ren H; Yang F; Diao K; Wei M; Mi X
Mol Med Rep; 2015 May; 11(5):3635-41. PubMed ID: 25591657
[TBL] [Abstract][Full Text] [Related]
14. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
17. Dephosphorylation of Girdin by PP2A inhibits breast cancer metastasis.
Li J; Enomoto A; Weng L; Sun L; Takahashi M
Biochem Biophys Res Commun; 2019 May; 513(1):28-34. PubMed ID: 30935690
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications for girdin protein expression in breast cancer.
Ling Y; Jiang P; Cui SP; Ren YL; Zhu SN; Yang JP; Du J; Zhang Y; Liu JY; Zhang B
Cancer Invest; 2011 Jul; 29(6):405-10. PubMed ID: 21649466
[TBL] [Abstract][Full Text] [Related]
20. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer.
Shibuta K; Ueo H; Furusawa H; Komaki K; Rai Y; Sagara Y; Kamada Y; Tamaki N
Breast Cancer; 2011 Oct; 18(4):292-8. PubMed ID: 20571962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]